Hospital Universitario de Salamanca -ko ikertzaileekin lankidetzan egindako argitalpenak (35)

2024

  1. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology

2023

  1. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study

    Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 4, pp. 794-801

  2. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

2022

  1. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

    Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067

  2. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

    Cancers, Vol. 14, Núm. 7

2021

  1. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

    Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938

  2. Clinical characterization and outcomes of 85 patients with neurosarcoidosis

    Scientific Reports, Vol. 11, Núm. 1

  3. Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients

    Joint Bone Spine, Vol. 88, Núm. 6

  4. Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer

    European Journal of Cardio-thoracic Surgery, Vol. 60, Núm. 1, pp. 81-88

  5. Seghi study: Defining the best surveillance strategy in hodgkin lymphoma after first-line treatment

    Cancers, Vol. 13, Núm. 10

2020

  1. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662

  2. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 72, Núm. 2, pp. 216-224

  3. Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-Sectional Study

    Arthritis Care and Research, Vol. 72, Núm. 6, pp. 822-828

2019

  1. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study

    Rheumatology International, Vol. 39, Núm. 12, pp. 2015-2024

  2. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

    Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

  3. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  4. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257

  5. Systemic phenotype of sarcoidosis associated with radiological stages. Analysis of 1230 patients

    European Journal of Internal Medicine, Vol. 69, pp. 77-85

2018

  1. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project

    Reumatologia Clinica, Vol. 14, Núm. 2, pp. 90-96

  2. Recommendations for the use of parenteral methotrexate in rheumatic diseases

    Reumatologia Clinica, Vol. 14, Núm. 3, pp. 142-149